Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410566 · ClinicalTrials.gov registry record · Phase 1
Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00410566 is a Phase 1 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 11 participants.
The verdict
NCT00410566, a Phase 1 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safe range of single doses of rhASM administered to adults with ASM deficiency.
Interventions
- DRUG rhASM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410566
The ClinicalTrials.gov registry entry for NCT00410566 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhASM is the first listed.
NCT00410566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00410566 about?
NCT00410566 is a clinical study titled "Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)". The purpose of this study is to determine the safe range of single doses of rhASM administered to adults with ASM deficiency.
What is the current status of trial NCT00410566?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2006-12. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00410566?
The interventions under investigation include: rhASM (DRUG).
Who is sponsoring clinical trial NCT00410566?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.